{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/etodolac-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962502",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962502_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"acalabrutinib\" outputclass=\"int-drug\">acalabrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  acalabrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acalabrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962503",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962503_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"acenocoumarol\" outputclass=\"int-drug\">Acenocoumarol</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Acenocoumarol   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Acenocoumarol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962504",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962504_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"aciclovir\" outputclass=\"int-drug\">aciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  aciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962505",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962505_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"adefovir\" outputclass=\"int-drug\">adefovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  adefovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adefovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962506",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962506_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"alendronate\" outputclass=\"int-drug\">alendronate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of gastrointestinal irritation when given with   alendronate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alendronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962507",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962507_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"aliskiren\" outputclass=\"int-drug\">aliskiren</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  aliskiren  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aliskiren</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962508",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962508_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"alprostadil\" outputclass=\"int-drug\">alprostadil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  alprostadil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alprostadil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962509",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962509_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"alteplase\" outputclass=\"int-drug\">Alteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Alteplase   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962510",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962510_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amikacin\" outputclass=\"int-drug\">amikacin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amikacin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amikacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962511",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962511_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amiloride  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962511_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amiloride\" outputclass=\"int-drug\">amiloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  amiloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amiloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962512",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962512_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amitriptyline\" outputclass=\"int-drug\">amitriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amitriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amitriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962513",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962513_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"amphotericin B\" outputclass=\"int-drug\">amphotericin B</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  amphotericin B  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amphotericin B</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962514",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962514_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"anagrelide\" outputclass=\"int-drug\">anagrelide</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  anagrelide  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Anagrelide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962515",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962515_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apixaban\" outputclass=\"int-drug\">Apixaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apixaban   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apixaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962516",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962516_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"argatroban\" outputclass=\"int-drug\">Argatroban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Argatroban   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Argatroban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962517",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962517_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"aspirin\" outputclass=\"int-drug\">aspirin</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  aspirin  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aspirin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962518",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962518_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  axitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962519",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962519_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"azilsartan\" outputclass=\"int-drug\">azilsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  azilsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azilsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962520",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962520_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bacitracin\" outputclass=\"int-drug\">bacitracin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bacitracin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacitracin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962521",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962521_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"beclometasone\" outputclass=\"int-drug\">beclometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   beclometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Beclometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962522",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962522_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">bemiparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bemiparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962522_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bemiparin\" outputclass=\"int-drug\">Bemiparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Bemiparin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bemiparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962523",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962523_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bendroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962523_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"bendroflumethiazide\" outputclass=\"int-drug\">bendroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   bendroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bendroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962524",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962524_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"betamethasone\" outputclass=\"int-drug\">betamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   betamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Betamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962525",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962525_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   bevacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962526",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962526_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bivalirudin\" outputclass=\"int-drug\">Bivalirudin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bivalirudin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bivalirudin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962527",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962527_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bosutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962528",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962528_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"budesonide\" outputclass=\"int-drug\">budesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   budesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Budesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962529",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962529_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"bumetanide\" outputclass=\"int-drug\">bumetanide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  bumetanide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bumetanide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962530",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962530_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   cabozantinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962531",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962531_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"candesartan\" outputclass=\"int-drug\">candesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  candesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Candesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962532",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962532_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cangrelor\" outputclass=\"int-drug\">cangrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cangrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cangrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962533",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962533_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"caplacizumab\" outputclass=\"int-drug\">caplacizumab</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   caplacizumab   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Caplacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"capreomycin\" outputclass=\"int-drug\">capreomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  capreomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capreomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"captopril\" outputclass=\"int-drug\">captopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  captopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Captopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">carbamazepine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  carbamazepine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  carboplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefaclor\" outputclass=\"int-drug\">cefaclor</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefaclor  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefaclor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefadroxil\" outputclass=\"int-drug\">cefadroxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefadroxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefadroxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefalexin\" outputclass=\"int-drug\">cefalexin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefalexin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefalexin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefazolin\" outputclass=\"int-drug\">cefazolin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefazolin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefazolin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefepime\" outputclass=\"int-drug\">cefepime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefepime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefepime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefixime\" outputclass=\"int-drug\">cefixime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefixime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefixime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefotaxime\" outputclass=\"int-drug\">cefotaxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefotaxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefotaxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefoxitin\" outputclass=\"int-drug\">cefoxitin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefoxitin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefoxitin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefradine\" outputclass=\"int-drug\">cefradine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefradine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefradine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftaroline\" outputclass=\"int-drug\">ceftaroline</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftaroline  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftaroline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftazidime\" outputclass=\"int-drug\">ceftazidime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftazidime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftazidime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftobiprole\" outputclass=\"int-drug\">ceftobiprole</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftobiprole  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftobiprole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftolozane\" outputclass=\"int-drug\">ceftolozane</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftolozane  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftolozane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ceftriaxone\" outputclass=\"int-drug\">ceftriaxone</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ceftriaxone  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceftriaxone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cefuroxime\" outputclass=\"int-drug\">cefuroxime</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cefuroxime  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cefuroxime</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  chlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962553_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlorothiazide\" outputclass=\"int-drug\">chlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   chlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  chlortalidone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962554_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"chlortalidone\" outputclass=\"int-drug\">chlortalidone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   chlortalidone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Chlortalidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"ciclesonide\" outputclass=\"int-drug\">ciclesonide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   ciclesonide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclesonide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ciclosporin  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962556_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ciclosporin\" outputclass=\"int-drug\">ciclosporin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  ciclosporin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciclosporin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cidofovir\" outputclass=\"int-drug\">cidofovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cidofovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cidofovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cilostazol\" outputclass=\"int-drug\">cilostazol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cilostazol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cilostazol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ciprofloxacin\" outputclass=\"int-drug\">ciprofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   ciprofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ciprofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  cisplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  citalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962561_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  citalopram  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"clodronate\" outputclass=\"int-drug\">clodronate</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of renal impairment when given with   clodronate .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clodronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  clomipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"clopidogrel\" outputclass=\"int-drug\">clopidogrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  clopidogrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clopidogrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"cobimetinib\" outputclass=\"int-drug\">cobimetinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   cobimetinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cobimetinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962566",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962566_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"colistimethate\" outputclass=\"int-drug\">Colistimethate</ph> <ph outputclass=\"int-substanceQualifier\">(particularly intravenous)</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of nephrotoxicity when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Colistimethate   (particularly intravenous)   potentially   increases   the risk of nephrotoxicity when given with   etodolac .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Colistimethate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962567",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962567_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabigatran\" outputclass=\"int-drug\">Dabigatran</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabigatran   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabigatran</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962568",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962568_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">dalteparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dalteparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962568_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dalteparin\" outputclass=\"int-drug\">Dalteparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Dalteparin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dalteparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962569",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962569_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"danaparoid\" outputclass=\"int-drug\">Danaparoid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Danaparoid   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Danaparoid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962570",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962570_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dapoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962570_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  dapoxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962571",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962571_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of renal impairment when given with</ph> <ph otherprops=\"daptomycin\" outputclass=\"int-drug\">daptomycin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of renal impairment when given with   daptomycin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962572",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962572_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  darbepoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962573",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962573_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dasatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962574",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962574_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deferasirox\" outputclass=\"int-drug\">deferasirox</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of gastrointestinal bleeding when given with   deferasirox .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deferasirox</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962575",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962575_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"deflazacort\" outputclass=\"int-drug\">deflazacort</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   deflazacort .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Deflazacort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962576",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962576_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"delafloxacin\" outputclass=\"int-drug\">delafloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   delafloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Delafloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962577",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962577_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"desmopressin\" outputclass=\"int-drug\">desmopressin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  desmopressin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desmopressin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962578",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962578_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"dexamethasone\" outputclass=\"int-drug\">dexamethasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   dexamethasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamethasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962579",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962579_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dipyridamole\" outputclass=\"int-drug\">dipyridamole</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dipyridamole  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dipyridamole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962580",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962580_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"dosulepin\" outputclass=\"int-drug\">dosulepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  dosulepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dosulepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962581",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962581_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"doxepin\" outputclass=\"int-drug\">doxepin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  doxepin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxepin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962582",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962582_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"drospirenone\" outputclass=\"int-drug\">drospirenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  drospirenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Drospirenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962583",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962583_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  duloxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962583_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  duloxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962584",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962584_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"edoxaban\" outputclass=\"int-drug\">Edoxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Edoxaban   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Edoxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962585",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962585_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eicosapentaenoic acid\" outputclass=\"int-drug\">eicosapentaenoic acid</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  eicosapentaenoic acid  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eicosapentaenoic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962586",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962586_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"enalapril\" outputclass=\"int-drug\">enalapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  enalapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enalapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962587",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962587_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">enoxaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  enoxaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962587_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enoxaparin\" outputclass=\"int-drug\">Enoxaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Enoxaparin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enoxaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962588",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962588_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  eplerenone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962588_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eplerenone\" outputclass=\"int-drug\">eplerenone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  eplerenone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eplerenone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962589",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962589_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoetin alfa  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962590",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962590_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoetin beta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962591",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962591_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoetin zeta  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962592",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962592_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"epoprostenol\" outputclass=\"int-drug\">epoprostenol</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  epoprostenol  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoprostenol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962593",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962593_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"eprosartan\" outputclass=\"int-drug\">eprosartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  eprosartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eprosartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962594",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962594_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eptifibatide\" outputclass=\"int-drug\">Eptifibatide</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eptifibatide   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eptifibatide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962595",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962595_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">Erlotinib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Erlotinib   is predicted to   increase   the risk of gastrointestinal perforation when given with   etodolac .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962596",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962596_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  escitalopram  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962596_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  escitalopram  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962597",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962597_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fludrocortisone\" outputclass=\"int-drug\">fludrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   fludrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962598",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962598_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  fluoxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962598_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  fluoxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962599",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962599_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"fluticasone\" outputclass=\"int-drug\">fluticasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   fluticasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluticasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962600",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962600_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  fluvoxamine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962600_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  fluvoxamine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962601",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962601_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fondaparinux\" outputclass=\"int-drug\">Fondaparinux</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fondaparinux   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fondaparinux</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962602",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962602_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"foscarnet\" outputclass=\"int-drug\">foscarnet</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  foscarnet  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Foscarnet</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962603",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962603_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"furosemide\" outputclass=\"int-drug\">furosemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  furosemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Furosemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962604",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962604_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"gabapentin\" outputclass=\"int-drug\">gabapentin</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  gabapentin  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gabapentin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962605",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962605_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962606",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962606_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"gentamicin\" outputclass=\"int-drug\">gentamicin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  gentamicin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gentamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962607",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962607_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"heparin\" outputclass=\"int-drug\">heparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  heparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962607_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"heparin\" outputclass=\"int-drug\">Heparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Heparin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Heparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962608",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962608_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  hydrochlorothiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962608_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydrochlorothiazide\" outputclass=\"int-drug\">hydrochlorothiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   hydrochlorothiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrochlorothiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962609",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962609_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"hydrocortisone\" outputclass=\"int-drug\">hydrocortisone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   hydrocortisone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydrocortisone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962610",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962610_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  hydroflumethiazide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962610_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"hydroflumethiazide\" outputclass=\"int-drug\">hydroflumethiazide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   hydroflumethiazide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroflumethiazide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962611",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962611_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal irritation when given with</ph> <ph otherprops=\"ibandronate\" outputclass=\"int-drug\">ibandronate</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution and monitor adverse effects</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of gastrointestinal irritation when given with   ibandronate .  Manufacturer advises caution and monitor adverse effects .    \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibandronate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962612",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962612_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ibrutinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962613",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962613_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ifosfamide\" outputclass=\"int-drug\">ifosfamide</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ifosfamide  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ifosfamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962614",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962614_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"iloprost\" outputclass=\"int-drug\">iloprost</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  iloprost  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iloprost</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962615",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962615_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  imatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962616",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962616_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"imidapril\" outputclass=\"int-drug\">imidapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  imidapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imidapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962617",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962617_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  imipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962618",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962618_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  indapamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962618_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"indapamide\" outputclass=\"int-drug\">indapamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   indapamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Indapamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962619",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962619_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  inotersen  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962619_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"inotersen\" outputclass=\"int-drug\">inotersen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   causes   bleeding, as can   inotersen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotersen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962620",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962620_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"irbesartan\" outputclass=\"int-drug\">irbesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  irbesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irbesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962621",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962621_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"lenvatinib\" outputclass=\"int-drug\">lenvatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  lenvatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenvatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962622",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962622_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"levofloxacin\" outputclass=\"int-drug\">levofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   levofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962623",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962623_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"lisinopril\" outputclass=\"int-drug\">lisinopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  lisinopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisinopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962624",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962624_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the concentration of   lithium .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962625",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962625_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"losartan\" outputclass=\"int-drug\">losartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  losartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Losartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962626",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962626_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  methotrexate  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962626_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of toxicity when given with</ph> <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   is predicted to   increase   the risk of toxicity when given with   methotrexate .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962627",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962627_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"methylprednisolone\" outputclass=\"int-drug\">methylprednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   methylprednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylprednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962628",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962628_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  metolazone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962628_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"metolazone\" outputclass=\"int-drug\">metolazone</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   metolazone .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metolazone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962629",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962629_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   (high-dose)   is predicted to   decrease   the efficacy of   mifamurtide .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962630",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962630_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"mometasone\" outputclass=\"int-drug\">mometasone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   mometasone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mometasone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962631",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962631_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"moxifloxacin\" outputclass=\"int-drug\">moxifloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   moxifloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moxifloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962632",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962632_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"neomycin\" outputclass=\"int-drug\">neomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  neomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Neomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962633",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962633_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicorandil\" outputclass=\"int-drug\">Nicorandil</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal perforation when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicorandil   is predicted to   increase   the risk of gastrointestinal perforation when given with   etodolac .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicorandil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962634",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962634_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nicotinic acid\" outputclass=\"int-drug\">Nicotinic acid</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nicotinic acid   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nicotinic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962635",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962635_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"nintedanib\" outputclass=\"int-drug\">nintedanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  nintedanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nintedanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962636",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962636_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"nortriptyline\" outputclass=\"int-drug\">nortriptyline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  nortriptyline  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nortriptyline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962637",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962637_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of seizures when given with</ph> <ph otherprops=\"ofloxacin\" outputclass=\"int-drug\">ofloxacin</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   potentially   increases   the risk of seizures when given with   ofloxacin .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ofloxacin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962638",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962638_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"olmesartan\" outputclass=\"int-drug\">olmesartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  olmesartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "137",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olmesartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962639",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962639_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"omega-3-acid ethyl esters\" outputclass=\"int-drug\">omega-3-acid ethyl esters</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  omega-3-acid ethyl esters  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "138",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Omega-3-acid ethyl esters</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962640",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962640_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  oxaliplatin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "139",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962641",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962641_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  paroxetine  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962641_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  paroxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "140",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962642",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962642_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"pazopanib\" outputclass=\"int-drug\">pazopanib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  pazopanib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "141",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pazopanib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962643",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962643_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  pemetrexed  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962643_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   is predicted to   increase   the exposure to   pemetrexed .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "142",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962644",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962644_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"penicillamine\" outputclass=\"int-drug\">penicillamine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  penicillamine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "143",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Penicillamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962645",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962645_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"pentamidine\" outputclass=\"int-drug\">pentamidine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  pentamidine  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "144",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentamidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962646",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962646_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"perindopril\" outputclass=\"int-drug\">perindopril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  perindopril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "145",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Perindopril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962647",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962647_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenindione\" outputclass=\"int-drug\">Phenindione</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenindione   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "146",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenindione</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962648",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962648_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"polymyxin b\" outputclass=\"int-drug\">polymyxin b</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  polymyxin b  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "147",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Polymyxin b</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962649",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962649_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ponatinib\" outputclass=\"int-drug\">ponatinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ponatinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "148",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ponatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962650",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962650_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"potassium aminobenzoate\" outputclass=\"int-drug\">potassium aminobenzoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  potassium aminobenzoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "149",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium aminobenzoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962651",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962651_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"potassium canrenoate\" outputclass=\"int-drug\">potassium canrenoate</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  potassium canrenoate  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "150",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium canrenoate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962652",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962652_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"potassium chloride\" outputclass=\"int-drug\">potassium chloride</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  potassium chloride  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "151",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Potassium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962653",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962653_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"prasugrel\" outputclass=\"int-drug\">prasugrel</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  prasugrel  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "152",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prasugrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962654",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962654_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"prednisolone\" outputclass=\"int-drug\">prednisolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   prednisolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "153",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Prednisolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962655",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962655_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"quinapril\" outputclass=\"int-drug\">quinapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  quinapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "154",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Quinapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962656",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962656_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ramipril\" outputclass=\"int-drug\">ramipril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ramipril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "155",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramipril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962657",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962657_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  regorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "156",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962658",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962658_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rivaroxaban\" outputclass=\"int-drug\">Rivaroxaban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rivaroxaban   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "157",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rivaroxaban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962659",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962659_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   ruxolitinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "158",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962660",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962660_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sertraline  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962660_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  sertraline  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "159",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962661",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962661_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sodium picosulfate\" outputclass=\"int-drug\">sodium picosulfate</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sodium picosulfate  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "160",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sodium picosulfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962662",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962662_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sorafenib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "161",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962663",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962663_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  spironolactone  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962663_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"spironolactone\" outputclass=\"int-drug\">spironolactone</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  spironolactone  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "162",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Spironolactone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962664",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962664_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"streptokinase\" outputclass=\"int-drug\">Streptokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Streptokinase   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "163",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962665",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962665_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"streptomycin\" outputclass=\"int-drug\">streptomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  streptomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "164",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962666",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962666_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  streptozocin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "165",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962667",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962667_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  sunitinib  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "166",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962668",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962668_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tacrolimus  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962668_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tacrolimus\" outputclass=\"int-drug\">tacrolimus</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  tacrolimus  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "167",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tacrolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962669",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962669_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"telmisartan\" outputclass=\"int-drug\">telmisartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  telmisartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "168",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Telmisartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962670",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962670_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tenecteplase\" outputclass=\"int-drug\">Tenecteplase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tenecteplase   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "169",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenecteplase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962671",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962671_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tenofovir disoproxil\" outputclass=\"int-drug\">tenofovir disoproxil</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tenofovir disoproxil  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "170",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tenofovir disoproxil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962672",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962672_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"ticagrelor\" outputclass=\"int-drug\">ticagrelor</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  ticagrelor  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "171",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ticagrelor</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962673",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962673_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">tinzaparin</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tinzaparin  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962673_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tinzaparin\" outputclass=\"int-drug\">Tinzaparin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Tinzaparin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "172",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tinzaparin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962674",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962674_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tirofiban\" outputclass=\"int-drug\">Tirofiban</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tirofiban   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "173",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tirofiban</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962675",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962675_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tobramycin\" outputclass=\"int-drug\">tobramycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tobramycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "174",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tobramycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962676",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962676_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"tolvaptan\" outputclass=\"int-drug\">tolvaptan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  tolvaptan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "175",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tolvaptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962677",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962677_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"torasemide\" outputclass=\"int-drug\">torasemide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  torasemide  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "176",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Torasemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962678",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962678_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trametinib\" outputclass=\"int-drug\">trametinib</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   trametinib   ; concurrent use might increase the risk of developing this effect .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "177",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trametinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962679",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962679_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trandolapril\" outputclass=\"int-drug\">trandolapril</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trandolapril  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "178",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trandolapril</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962680",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962680_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   trastuzumab emtansine   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "179",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962681",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962681_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"treprostinil\" outputclass=\"int-drug\">treprostinil</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  treprostinil  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "180",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Treprostinil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962682",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962682_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of gastrointestinal bleeding when given with</ph> <ph otherprops=\"triamcinolone\" outputclass=\"int-drug\">triamcinolone</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   increases   the risk of gastrointestinal bleeding when given with   triamcinolone .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "181",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamcinolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962683",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962683_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  triamterene  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962683_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"triamterene\" outputclass=\"int-drug\">triamterene</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  triamterene  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "182",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Triamterene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962684",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962684_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trimethoprim  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962684_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  etodolac  and  trimethoprim  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962684_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimethoprim\" outputclass=\"int-drug\">trimethoprim</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "3",
							"hasTextContent": "Both  etodolac  and  trimethoprim  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "183",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimethoprim</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962685",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962685_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"trimipramine\" outputclass=\"int-drug\">trimipramine</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  trimipramine  can increase the risk of hyponatraemia. \n\n"
						}
					],
					"hasOrder": "184",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trimipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962686",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962686_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"urokinase\" outputclass=\"int-drug\">Urokinase</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Urokinase   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "185",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Urokinase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962687",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962687_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"valaciclovir\" outputclass=\"int-drug\">valaciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  valaciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "186",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valaciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962688",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962688_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  valganciclovir  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "187",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962689",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962689_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"valsartan\" outputclass=\"int-drug\">valsartan</ph> can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone).</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  valsartan  can increase the risk of hyperkalaemia (hyperkalaemia is particularly notable when ACE inhibitors or angiotensin-II receptor antagonists are given with spironolactone or eplerenone). \n\n"
						}
					],
					"hasOrder": "188",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valsartan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962690",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962690_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"vancomycin\" outputclass=\"int-drug\">vancomycin</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  vancomycin  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "189",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vancomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962691",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962691_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  venlafaxine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "190",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962692",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962692_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"volanesorsen\" outputclass=\"int-drug\">volanesorsen</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid depending on platelet count—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etodolac   causes   bleeding, as can   volanesorsen   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises avoid depending on platelet count—consult product literature .    \n\n"
						}
					],
					"hasOrder": "191",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Volanesorsen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962693",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962693_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of bleeding. </p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  vortioxetine  can increase the risk of bleeding.  \n\n"
						}
					],
					"hasOrder": "192",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962694",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962694_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"warfarin\" outputclass=\"int-drug\">Warfarin</ph> <ph outputclass=\"int-effect\">causes</ph> <ph outputclass=\"int-parameter\">bleeding, as can</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> <ph outputclass=\"int-substanceQualifier\">; concurrent use might increase the risk of developing this effect</ph>. <ph outputclass=\"int-action\">Manufacturer advises use with caution or avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Warfarin   causes   bleeding, as can   etodolac   ; concurrent use might increase the risk of developing this effect .  Manufacturer advises use with caution or avoid .    \n\n"
						}
					],
					"hasOrder": "193",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Warfarin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962695",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962695_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph> can increase the risk of hyponatraemia.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  xipamide  can increase the risk of hyponatraemia. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962695_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">Etodolac</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of acute renal failure when given with</ph> <ph otherprops=\"xipamide\" outputclass=\"int-drug\">xipamide</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Etodolac   increases   the risk of acute renal failure when given with   xipamide .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "194",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Xipamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962696",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962696_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">zidovudine</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  zidovudine  can increase the risk of nephrotoxicity. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962696_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"zidovudine\" outputclass=\"int-drug\">Zidovudine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of haematological toxicity when given with</ph> <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "2",
							"hasTextContent": "Zidovudine   increases   the risk of haematological toxicity when given with   etodolac .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "195",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zidovudine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962697",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/etodolac-2#bnf_i1643857962697_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"etodolac\" outputclass=\"int-heading-drug\">etodolac</ph> and <ph otherprops=\"zoledronate\" outputclass=\"int-drug\">zoledronate</ph> can increase the risk of nephrotoxicity.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  etodolac  and  zoledronate  can increase the risk of nephrotoxicity. \n\n"
						}
					],
					"hasOrder": "196",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zoledronate</title>"
					}
				}
			],
			"hasSearchLabel": " Etodolac  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/etodolac-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Etodolac </title>"
			},
			"rdfs:label": "etodolac"
		}
	]
}